EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups

Erkan Ozcan iD, Ivo Gokmen iD, Fahri Akgul, Fatma Akdag Kahvecioglu, Abdussamet Celebi, Osman Kostek, Ilhan Hacıbekiroglu, Bulent Erdogan iD

The Breast Journal · 2025-01 · 2025 (1)

DOI: 10.1155/tbj/5577345 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Breast Journal, online erschienen am 27.06.2025. Verfasst von Erkan Ozcan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical impact of HER2‐low status on the efficacy of cyclin‐dependent kinase 4/6 inhibitor (CDK4/6i). Therapy in patients with hormone receptor‐positive (HR+), HER2‐negative metastatic breast cancer (MBC) remains unclear.

Methods

We conducted a multicenter, retrospective analysis including 212 female patients with HR+/HER2−MBC treated with CDK4/6is between 2018 and 2022. Patients were classified as HER2‐zero or HER2‐low based on immunohistochemistry results. Progression‐free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups.

Results

Median PFS was 16.0 months in the HER2‐low group and 13.9 months in the HER2‐zero group ( p = 0.40). In first‐line therapy, PFS was numerically longer in the HER2‐low group (18.6 vs. 14.9 months; p = 0.26) although this was not statistically significant. ORR was 71.4% in HER2‐low and 62% in HER2‐zero patients, and DCR was 86.6% and 82%, respectively (both p > 0.05). Subgroup analyses showed that within the HER2‐low group, patients with ≥ 2 metastatic sites had significantly shorter PFS compared with those with a single site (14.1 vs. 20.2 months; p = 0.02), and the presence of visceral metastases was associated with poorer PFS ( p = 0.003). Overall survival (OS) data were immature, with only 24.6% of the patients deceased at the time of analysis.

Conclusion

HER2 status did not significantly impact treatment outcomes with CDK4/6i in HR+/HER2‐negative MBC patients. However, subgroup analyses indicated that metastatic burden, particularly the number of metastatic sites and the presence of visceral disease, may adversely influence PFS. These findings highlight the need for further validation in larger prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsHumansFemaleMiddle AgedRetrospective StudiesAgedAdultReceptors, EstrogenReceptors, ProgesteroneAged, 80 and overProgression-Free SurvivalNeoplasm Metastasis

Stichwörter der Autor:innen

CDK4/6 inhibitorsHER2 lowHER2 zeroHR-positive breast cancerprogression-free survival

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanCDK6 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
  • Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
  • Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.

ORCID-Profile: Erkan Ozcan, Ivo Gokmen, Bulent Erdogan

Zitieren

APA

Ozcan, E., Gokmen, I., Akgul, F., Kahvecioglu, F. A., Celebi, A., Kostek, O., Hacıbekiroglu, I., & Erdogan, B. (2025). Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups. The Breast Journal, 2025(1). https://doi.org/10.1155/tbj/5577345

Vancouver

Ozcan E, Gokmen I, Akgul F, Kahvecioglu FA, Celebi A, Kostek O, et al. Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups. The Breast Journal. 2025;2025(1). doi:10.1155/tbj/5577345

BibTeX
@article{Ozcan2025,
  author = {Ozcan, Erkan and Gokmen, Ivo and Akgul, Fahri and Kahvecioglu, Fatma Akdag and Celebi, Abdussamet and Kostek, Osman and Hacıbekiroglu, Ilhan and Erdogan, Bulent},
  title = {Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups},
  journal = {The Breast Journal},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/tbj/5577345}
}
Kostenlos starten →